Posted by Noobie123 > Dec 7, 2020 8:10 PM | Report Abuse
Ular, Founder of Kanger is the MD himself, a China national, based in China, JV with Chinese local Government...workers also got ESOS...they are serious businessmen. You think got hanky panky or not?
If we look at PMETAL, then it's no reason to ignore PA Resources Bhd. They both have similar business, Aluminium billets and tolling. It will soon likes gloves, demand exceed supply, then the asp will continue go up every month. Their main customer First Solar is a very big solar company in USA, its PA client. From our sources we believe that they will renew this contract soon, and with even bigger amount, because BIDEN win the USA election. PA is on a strong recovery trend in technical and fundamental and global Aluminium price and demand is keep increasing and high demand this year. PA doing share consolidate, which we can see VIVOCOM and many other case after split price will goreng and limit up to sky very soon. First solar is their client, which is going to benefit them even more in future after Biden in president place. PA price is just waking up, it will continue go up until share consolidate done, and go even higher. Stay tune!
Never ending PP tranche. After PP completion, share float ballooned so big will be difficult to climb up unless syndicate wallop and hold. Else 1-2 sen gain follow by dumping
anyone is free to call the company to clarify the actual meaning of 3rd tranche. why left out the actual PP qty to be issued. mislead shareholders? correct?
Assuming all the outstanding RCN are converted and 90,000,000 Share Options are exercised prior to the implementation of the Proposed Private Placement, the Company's enlarged number of issued Shares will be 1,934,853,420 Kanger Shares. As such, a total of up to 386,970,684 new Kanger Shares ("Placement Share(s)"), representing 20% of the enlarged number of issued shares of Kanger, may be issued pursuant to the Proposed Private Placement. The actual number of Placement Shares to be issued pursuant to the Proposed
First 2 tranches 380mil completed the 20% of the PP shares. so the 3rd tranche cannot be 70mil. I suspect it is a new 20% of new PP shares of 2255mil x 20% = 450mil new PP shares. correct?
@UlarSawa It is stated here "Reference is made to the announcements dated 13 October 2020, 21 October 2020, 9 November 2020, 10 November 2020, 17 November 2020, 18 November 2020, 20 November 2020, 24 November 2020, 25 November 2020 and 26 November 2020 in relation to the Private Placement."
@UlarSawa If you notice Kangers Bursa Announcements, first they will announce the fixed issue price for that particular tranche first (See example of announcement for issue price fixed for 2nd tranche below) followed by announcement of the number of private placement shares issued for 2nd tranche which they did announce subsequently. So they should be announcing the number of private placement shares issued for 3rd tranche anytime soon.
now 380mil issued so far. left few million only if based on the 1st announcement max 386mil shares. 6 mil also want to raise fund kah. why not added into 2nd tranche? correct?
i'm also confused with this kanger pp..20% done..24th nov announcement 1st tranche 183,237,544 listed..26th nov 2nd tranche 195,973,879 listed..3rd tranche announced? how many left? i tot 20% aldy done..super confused..any enlightenment?
MOH staff. dont ask me. Ask the company person in charge. I also found abit funny only. time to rest liao. tomorrow come again. Up or down? bye bye. ok.
@mikho69 @UlarSawa After digging up all the bursa announcements, the answer is as follows : Total number of shares to be issued for PP is 386,970,684 (Please refer to the link below). Hence, after deducting the no. of PP shares issued for 1st tranche ie. 183,237,544 and no. of PP shares issued for 2nd tranche ie. 195,973,879, the remaining balance should be only 7,759,261 shares left.
However, if we take into account what @x3shphere mentioned above regarding the conversion of redeemable convertible notes (RCN) ie 3,703,703 shares, then total remaining would be 7,759,261 PP + 3,703,703 RCN = 11,462,964 remaining shares (Disclaimer : I have no idea what RCN is and whether it should be added to the number of remaining private placement shares. Perhaps some expert here can enlighten us on this matter)
Kanger should be making the announcement soon regarding the number of shares issued for the 3rd tranche which would be the final tranche and private placement would be complete.
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Please refer to the full announcement as attached.
DEWAN RAKYAT's decision on securing vaccine from PFIZER and Covax only may be good for Kanger whose supplier, SinoPharm, is a public concern of the government of China, a member of covax. Hence, clinical test results of Sinopharm will be accepted by our health ministry and no further clinical test in Malaysia is required. Other local vaccine related companies must get approval from the ministry of health for conducting clinical test of vaccine in Malaysia.
eyehunter, good advice. Lets waste no more valuable time on kanger and start focusing on other potential star performers instead with our limited research hours.
@NoEmo Actually, it Is not a requirement to conduct local clinical trials of vaccines in Malaysia in order to obtain approval from NPRA, MOH. Approval will be based on assessment of the data from preclinical, phase I, phase II and phase III clinical trials conducted by the manufacturer anywhere in the world.
Eyehunter, we shouldn't spend even a second on this stock to get more negative qi that may jeopardize our quest for better ROI. Lets leave this forum together for good. ........................................................................
Of all stocks, why delved into such a problem stock like Kanger. Shouldn't put a Sen in this stock.
It is too many news too many postings here tat has made u anxious impatient like it has bin years waiting for SINOPHARM vaccine whereas SINOPHARM is actually ahead of many others
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Orlando
4,909 posts
Posted by Orlando > 2020-12-07 21:19 | Report Abuse
By now Nur shd b controlling a big % of KANGER